Bortezomib Inhibits Nuclear Factor-κB–Dependent Survival and Has Potent <i>In vivo</i> Activity in MesotheliomaAndrea Sartore‐Bianchi(Azienda Socio Sanitaria Territoriale Grande Ospedale Metropolitano Niguarda), Luciano MuttiClinical Cancer ResearchOctober 1, 200710.1158/1078-0432.ccr-07-0536Cited by 93SaveCiteExport RISWatch citationsRelated PapersMulti-Determinants Analysis of Molecular Alterations for Predicting Clinical Benefit to EGFR-Targeted Monoclonal Antibodies in Colorectal Cancer|PLoS ONE|2009|257Circulating tumor DNA to guide rechallenge with panitumumab in metastatic colorectal cancer: the phase 2 CHRONOS trial|Nature Medicine|2022|251